Brigatinib
Brigatinib is a pharmaceutical drug with 34 clinical trials. Currently 9 active trials ongoing. Historical success rate of 75.0%.
Success Metrics
Based on 12 completed trials
Phase Distribution
Phase Distribution
8
Early Stage
17
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
57.1%
12 of 21 finished
42.9%
9 ended early
9
trials recruiting
34
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Using Tumor Models to Determine Treatments
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
Clinical Trials (34)
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Using Tumor Models to Determine Treatments
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 34